Skip to main content
Top
Published in: Autoimmunity Highlights 1/2020

01-12-2020 | Venous Thrombosis | Original Research

Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

Authors: Ilan Volkov, Luciana Seguro, Elaine P. Leon, László Kovács, Dirk Roggenbuck, Peter Schierack, Boris Gilburd, Andrea Doria, Maria G. Tektonidou, Nancy Agmon-Levin

Published in: Autoimmunity Highlights | Issue 1/2020

Login to get access

Abstract

Background

Specific anti-phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require specific therapies. Non-criteria aPLs are rarely evaluated and their role is yet to be defined. In the current study, we aimed to examine the association between criteria and non-criteria aPLs and APS phenotypes.

Methods

Serum samples from 188 subjects, 130 APS patients and 58 controls were analyzed for the presence of 20 aPLs (IgG and IgM isotypes to cardiolipin (CL), beta2-glycoprotein1 (β2GP1), phosphatidic acid (P-acid), phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), annexin-5 (AN) and prothrombin (PT) using a line immunoassay (GA Generic Assays, Germany). Sero-positivity to the different aPLs/aPLs profiles was correlated to APS phenotypes (i.e. arterial thrombosis, CNS manifestations, venous thrombosis, relapsing disease, obstetric morbidity).

Results

In this cohort, arterial thrombosis was associated with accumulative number of ≥ 7/20 aPLs evaluated (OR 4.1; CI 95% 1.9–96, p = 0.001) as well as the sole presence of aPT (IgG) (OR 2.3;CI 95% 1.1–5.1, p = 0.03). CNS manifestations were linked with a profile of 4 aPLs (IgG): aPT, aPG, aPI and aAN (OR 2.6;CI 95% 1.1–6.3, p = 0.03). Symptom-free period of ≥ 3 years was linked with lower number of aPLs and the presence of aPI (IgG) (OR 3.0;CI 95% 1.08–8.1, p < 0.05) or aAN (IgG) (OR 3.4;CI 95% 1.08–10.9, p < 0.05). APS related pregnancy morbidity correlated with a profile of 2 aPLs (IgG): aCL and aPS (OR 2.9; CI 95% 1.3–6.5, p < 0.05) or the sole presence of aAN (IgG) (OR 2.8; CI 95% 1.02–8, p = 0.05).

Conclusion

In this study, we observed an association between specific criteria/non-criteria aPLs or aPLs profiles and clinical phenotypes of APS. Our data suggest that examination of a wider variety of aPLs may allow better characterization of APS.
Literature
1.
go back to reference Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:18005.PubMedCrossRef Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:18005.PubMedCrossRef
2.
go back to reference Agmon-Levin N, Shoenfeld Y. The spectrum between antiphospholipid syndrome and systemic lupus erythematosus. Clin Rheumatol. 2014;33(3):293–5.PubMedCrossRef Agmon-Levin N, Shoenfeld Y. The spectrum between antiphospholipid syndrome and systemic lupus erythematosus. Clin Rheumatol. 2014;33(3):293–5.PubMedCrossRef
3.
go back to reference Hughes GR, Shoenfeld Y. Antiphospholipid antibody testing—slow progress? Int J Clin Pract. 2012;66(6):533–5.PubMedCrossRef Hughes GR, Shoenfeld Y. Antiphospholipid antibody testing—slow progress? Int J Clin Pract. 2012;66(6):533–5.PubMedCrossRef
4.
go back to reference Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135(Suppl 1):S56–9.PubMedCrossRef Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135(Suppl 1):S56–9.PubMedCrossRef
5.
go back to reference Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedCrossRef Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMedCrossRef
6.
go back to reference Roggenbuck D, Egerer K, von Landenberg P, et al. Antiphospholipid antibody profiling: time for a new technical approach? Autoimmun Rev. 2012;11(11):821–6.PubMedCrossRef Roggenbuck D, Egerer K, von Landenberg P, et al. Antiphospholipid antibody profiling: time for a new technical approach? Autoimmun Rev. 2012;11(11):821–6.PubMedCrossRef
7.
8.
go back to reference Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost. 2012;38(4):339–47.PubMedCrossRef Les I, Ruiz-Irastorza G, Khamashta MA. Intensity and duration of anticoagulation therapy in antiphospholipid syndrome. Semin Thromb Hemost. 2012;38(4):339–47.PubMedCrossRef
9.
go back to reference Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504–12.PubMedCrossRef Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64(2):504–12.PubMedCrossRef
10.
go back to reference Yelnik CM, Urbanski G, Drumez E, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26(2):163–9.PubMedCrossRef Yelnik CM, Urbanski G, Drumez E, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26(2):163–9.PubMedCrossRef
11.
go back to reference Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.PubMedCrossRef Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.PubMedCrossRef
12.
go back to reference Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145–50.PubMedCrossRef Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011;70(1):145–50.PubMedCrossRef
13.
go back to reference Sciascia S, Coloma-Bazan E, Radin M, et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? Autoimmun Rev. 2017;16(11):1109–14.PubMedCrossRef Sciascia S, Coloma-Bazan E, Radin M, et al. Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion? Autoimmun Rev. 2017;16(11):1109–14.PubMedCrossRef
14.
go back to reference Mekinian A, Alijotas-Reig J, Carrat F, et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev. 2017;16(7):730–4.PubMedCrossRef Mekinian A, Alijotas-Reig J, Carrat F, et al. Refractory obstetrical antiphospholipid syndrome: features, treatment and outcome in a European multicenter retrospective study. Autoimmun Rev. 2017;16(7):730–4.PubMedCrossRef
15.
go back to reference Leone A, Radin M, Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2017;16(5):469–77.PubMedCrossRef Leone A, Radin M, Almarzooqi AM, et al. Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: a systematic review. Autoimmun Rev. 2017;16(5):469–77.PubMedCrossRef
16.
go back to reference Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14.PubMedCrossRef Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401–14.PubMedCrossRef
17.
go back to reference Sciascia S, Bertolaccini ML. Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. Lupus. 2014;23(12):1309–12.PubMedCrossRef Sciascia S, Bertolaccini ML. Antibodies to phosphatidylserine/prothrombin complex and the antiphospholipid syndrome. Lupus. 2014;23(12):1309–12.PubMedCrossRef
18.
go back to reference Mekinian A, Bourrienne MC, Carbillon L, et al. Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies. Semin Arthritis Rheum. 2016;46(2):232–7.PubMedCrossRef Mekinian A, Bourrienne MC, Carbillon L, et al. Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: prevalence and treatment efficacy in pregnancies. Semin Arthritis Rheum. 2016;46(2):232–7.PubMedCrossRef
19.
go back to reference Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614–24.PubMedCrossRef Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56(4):614–24.PubMedCrossRef
20.
go back to reference Wolgast LR, Arslan AA, Wu XX, Beyda JN, Pengo V, Rand JH. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes. J Thromb Haemost. 2017;15(7):1412–21.PubMedCrossRef Wolgast LR, Arslan AA, Wu XX, Beyda JN, Pengo V, Rand JH. Reduction of annexin A5 anticoagulant ratio identifies antiphospholipid antibody-positive patients with adverse clinical outcomes. J Thromb Haemost. 2017;15(7):1412–21.PubMedCrossRef
21.
go back to reference Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354–64.PubMedCrossRef Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354–64.PubMedCrossRef
22.
go back to reference Egerer K, Roggenbuck D, Buttner T, et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther. 2011;13(4):R118.PubMedPubMedCentralCrossRef Egerer K, Roggenbuck D, Buttner T, et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther. 2011;13(4):R118.PubMedPubMedCentralCrossRef
23.
go back to reference Roggenbuck D, Somma V, Schierack P, Borghi MO, Meroni PL. Autoantibody profiling in APS. Lupus. 2014;23(12):1262–4.PubMedCrossRef Roggenbuck D, Somma V, Schierack P, Borghi MO, Meroni PL. Autoantibody profiling in APS. Lupus. 2014;23(12):1262–4.PubMedCrossRef
24.
go back to reference Roggenbuck D, Borghi MO, Somma V, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18(1):111.PubMedPubMedCentralCrossRef Roggenbuck D, Borghi MO, Somma V, et al. Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers. Arthritis Res Ther. 2016;18(1):111.PubMedPubMedCentralCrossRef
25.
go back to reference Nalli C, Somma V, Andreoli L, et al. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights. 2018;9(1):6.PubMedPubMedCentralCrossRef Nalli C, Somma V, Andreoli L, et al. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Auto Immun Highlights. 2018;9(1):6.PubMedPubMedCentralCrossRef
26.
go back to reference Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmun Rev. 2012;11(8):577–80.PubMedCrossRef Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A. High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmun Rev. 2012;11(8):577–80.PubMedCrossRef
27.
go back to reference Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007;5(6):1158–64.PubMedCrossRef Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007;5(6):1158–64.PubMedCrossRef
28.
go back to reference Pengo V. APS–controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127(Suppl 3):S51–2.PubMedCrossRef Pengo V. APS–controversies in diagnosis and management, critical overview of current guidelines. Thromb Res. 2011;127(Suppl 3):S51–2.PubMedCrossRef
29.
go back to reference Cervera R, Conti F, Doria A, Iaccarino L, Valesini G. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev. 2012;11(8):581–4.PubMedCrossRef Cervera R, Conti F, Doria A, Iaccarino L, Valesini G. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev. 2012;11(8):581–4.PubMedCrossRef
30.
go back to reference Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3(6):1231–8.PubMedCrossRef Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3(6):1231–8.PubMedCrossRef
31.
go back to reference Zhang S, Wu Z, Li J, et al. Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events. Rheumatol Int. 2017;37(4):579–84.PubMedCrossRef Zhang S, Wu Z, Li J, et al. Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events. Rheumatol Int. 2017;37(4):579–84.PubMedCrossRef
32.
go back to reference Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun. 2000;15(2):101–5.PubMedCrossRef Galli M. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome? J Autoimmun. 2000;15(2):101–5.PubMedCrossRef
33.
go back to reference Yelnik CM, Kozora E, Appenzeller S. Non-stroke central neurologic manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2016;18(2):11.PubMedCrossRef Yelnik CM, Kozora E, Appenzeller S. Non-stroke central neurologic manifestations in Antiphospholipid Syndrome. Curr Rheumatol Rep. 2016;18(2):11.PubMedCrossRef
34.
go back to reference Iaccarino L, Ghirardello A, Canova M, et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev. 2011;10(9):553–8.PubMedCrossRef Iaccarino L, Ghirardello A, Canova M, et al. Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev. 2011;10(9):553–8.PubMedCrossRef
35.
go back to reference Amoroso A, Mitterhofer AP, Del Porto F, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol. 2003;64(2):265–73.PubMedCrossRef Amoroso A, Mitterhofer AP, Del Porto F, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol. 2003;64(2):265–73.PubMedCrossRef
36.
go back to reference Jackson WG, Oromendia C, Unlu O, et al. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320–4.PubMedPubMedCentralCrossRef Jackson WG, Oromendia C, Unlu O, et al. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320–4.PubMedPubMedCentralCrossRef
37.
go back to reference Nalli C, Andreoli L, Casu C, Tincani A. Management of recurrent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep. 2014;16(3):405.PubMedCrossRef Nalli C, Andreoli L, Casu C, Tincani A. Management of recurrent thrombosis in antiphospholipid syndrome. Curr Rheumatol Rep. 2014;16(3):405.PubMedCrossRef
38.
go back to reference Legault KJ, Ugarte A, Crowther MA, Ruiz-Irastorza G. Prevention of recurrent thrombosis in Antiphospholipid Syndrome: different from the general population? Curr Rheumatol Rep. 2016;18(5):26.PubMedCrossRef Legault KJ, Ugarte A, Crowther MA, Ruiz-Irastorza G. Prevention of recurrent thrombosis in Antiphospholipid Syndrome: different from the general population? Curr Rheumatol Rep. 2016;18(5):26.PubMedCrossRef
39.
go back to reference Amory CF, Levine SR, Brey RL, et al. Antiphospholipid Antibodies and Recurrent Thrombotic events: persistence and Portfolio. Cerebrovasc Dis. 2015;40(5–6):293–300.PubMedPubMedCentralCrossRef Amory CF, Levine SR, Brey RL, et al. Antiphospholipid Antibodies and Recurrent Thrombotic events: persistence and Portfolio. Cerebrovasc Dis. 2015;40(5–6):293–300.PubMedPubMedCentralCrossRef
40.
go back to reference Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol. 2017;29(6):397–403.PubMedCrossRef Schreiber K, Radin M, Sciascia S. Current insights in obstetric antiphospholipid syndrome. Curr Opin Obstet Gynecol. 2017;29(6):397–403.PubMedCrossRef
41.
go back to reference Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. The European registry on obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406–14.PubMedCrossRef Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. The European registry on obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406–14.PubMedCrossRef
42.
go back to reference Gris JC, Cyprien F, Bouvier S, et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. World J Biol Psychiatry. 2017;20:1–13. Gris JC, Cyprien F, Bouvier S, et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. World J Biol Psychiatry. 2017;20:1–13.
43.
go back to reference Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525 e521.CrossRef Saccone G, Berghella V, Maruotti GM, et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525 e521.CrossRef
44.
go back to reference Ornoy A, Yacobi S, Matalon ST, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003;12(7):573–8.PubMedCrossRef Ornoy A, Yacobi S, Matalon ST, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus. 2003;12(7):573–8.PubMedCrossRef
45.
go back to reference Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460–9.PubMedCrossRef Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460–9.PubMedCrossRef
46.
go back to reference Becarevic M. The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. J Thromb Thrombolysis. 2016;42(4):552–7.PubMedCrossRef Becarevic M. The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. J Thromb Thrombolysis. 2016;42(4):552–7.PubMedCrossRef
47.
go back to reference Zhang S, Wu Z, Li J, et al. Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. Clin Rheumatol. 2017;36(2):407–12.PubMedCrossRef Zhang S, Wu Z, Li J, et al. Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndrome. Clin Rheumatol. 2017;36(2):407–12.PubMedCrossRef
48.
go back to reference Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of non-criteria antibodies for the diagnosis and clinical management. Haematologica. 2020;105(3):562–72.PubMedPubMedCentralCrossRef Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of non-criteria antibodies for the diagnosis and clinical management. Haematologica. 2020;105(3):562–72.PubMedPubMedCentralCrossRef
49.
go back to reference Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity–friends or foes? Trends Immunol. 2009;30(8):409–14.PubMedCrossRef Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity–friends or foes? Trends Immunol. 2009;30(8):409–14.PubMedCrossRef
50.
go back to reference Zinger H, Sherer Y, Goddard G, et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus. 2009;18(13):1149–53.PubMedCrossRef Zinger H, Sherer Y, Goddard G, et al. Common infectious agents prevalence in antiphospholipid syndrome. Lupus. 2009;18(13):1149–53.PubMedCrossRef
51.
go back to reference Kasahara H, Matsuura E, Kaihara K, et al. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol. 2005;17(12):1533–42.PubMedCrossRef Kasahara H, Matsuura E, Kaihara K, et al. Antigenic structures recognized by anti-beta2-glycoprotein I auto-antibodies. Int Immunol. 2005;17(12):1533–42.PubMedCrossRef
52.
go back to reference Thaler MA, Bietenbeck A, Steigerwald U, et al. Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS ONE. 2019;14(7):e0220033.PubMedPubMedCentralCrossRef Thaler MA, Bietenbeck A, Steigerwald U, et al. Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. PLoS ONE. 2019;14(7):e0220033.PubMedPubMedCentralCrossRef
Metadata
Title
Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome
Authors
Ilan Volkov
Luciana Seguro
Elaine P. Leon
László Kovács
Dirk Roggenbuck
Peter Schierack
Boris Gilburd
Andrea Doria
Maria G. Tektonidou
Nancy Agmon-Levin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Autoimmunity Highlights / Issue 1/2020
Print ISSN: 2038-0305
Electronic ISSN: 2038-3274
DOI
https://doi.org/10.1186/s13317-020-00131-3

Other articles of this Issue 1/2020

Autoimmunity Highlights 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.